Harrow Health, Inc. (HROW)
| Market Cap | 191.11M |
| Revenue (ttm) | 79.15M |
| Net Income (ttm) | -21.13M |
| Shares Out | 27.03M |
| EPS (ttm) | -0.78 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 94,705 |
| Open | 6.64 |
| Previous Close | 6.41 |
| Day's Range | 6.45 - 7.13 |
| 52-Week Range | 5.40 - 12.99 |
| Beta | 0.90 |
| Analysts | Buy |
| Price Target | 17.72 (+150.6%) |
| Earnings Date | Aug 9, 2022 |
About HROW
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commerc... [Read more...]
Financial Performance
In 2021, Harrow Health's revenue was $72.48 million, an increase of 48.30% compared to the previous year's $48.87 million. Losses were -$18.01 million, 436.4% more than in 2020.
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for HROW stock is "Buy." The 12-month stock price forecast is 17.72, which is an increase of 150.64% from the latest price.
News
Harrow Health Announces Launch of IOPIDINE® 1% and MAXITROL® in the United States
NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic‑focused healthcare company, today announced the completion of the transfer to Harrow of the New Drug Applications (ND...
Harrow Health Announces First Quarter 2022 Financial Results
NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic‑focused healthcare company, today announced results for the first quarter ended March 31, 2022. The Company also post...
Melt Pharmaceuticals Announces MELT-210 Top-Line Results of Phase 1 Pharmacokinetics (PK) Study for Procedural Sedation
NASHVILLE, Tenn.--(BUSINESS WIRE)--Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing novel approaches for procedural sedation and analgesia, today announced top-line results...
Harrow Health to Participate in B. Riley Securities' Annual Neuro & Ophthalmology Investor Conference
NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow Health, Inc. (Nasdaq: HROW), an ophthalmic‑focused healthcare company, today announced that Mark L. Baum, Chief Executive Officer, and Andrew Boll, Chief Financ...
Harrow Health to Announce First Quarter 2022 Financial Results on May 5, 2022
NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow Health, Inc. (Nasdaq: HROW), an ophthalmic-focused healthcare company, today announced that it will release its financial results for the first quarter ended Ma...
Harrow Health Announces Appointments to Its Board of Directors
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow Health, Inc. (Nasdaq: HROW), an ophthalmic-focused healthcare company, today announced the appointments of Perry J. Sternberg and Marty Makary, M.D., ...
Harrow Health Announces Fourth Quarter and Year-End 2021 Financial Results
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic‑focused healthcare company, today announced results for the fourth quarter and year ended December 31, 2021...
Melt Pharmaceuticals Names Experienced Executive Brad Osborne as Chief Financial Officer
NASHVILLE, Tenn.--(BUSINESS WIRE)--Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing first‑in‑class medicines for sedation and analgesia, today announced the addition of Bra...
Harrow Health to Announce Fourth Quarter and Year-End 2021 Financial Results on March 10, 2022
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic‑focused healthcare company, today announced that it will release its financial results for the fourth quart...
Harrow Health Announces FDA Acceptance of New Drug Application for AMP-100
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow Health, Inc. (Nasdaq: HROW), an ophthalmic‑focused healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has accepted t...
Harrow Health to Present at Aegis Virtual Conference
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced that Mark L. Baum, Chief Executive Officer, and Andrew Boll, Ch...
Two Insider Moonshots Rising on Sudden Buying
Biotech insiders are among the most important investors to pay close attention to. Here are two that show good signs for the future.
Harrow Health Publishes Corporate Transparency Report
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow Health, Inc. (Nasdaq: HROW), an ophthalmic‑focused healthcare company, today announced that its inaugural 2022 Corporate Transparency Report is now av...
Harrow Health to Participate in H.C. Wainwright BioConnect Conference
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced that Mark L. Baum, Chief Executive Officer, and Andrew Boll, Ch...
Melt Pharmaceuticals Submits INDs for MELT‑210 and MELT-400 to FDA
NASHVILLE, Tenn.--(BUSINESS WIRE)--Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing first‑in‑class medicines for sedation and analgesia, today announced the filing of two i...
Harrow Health Acquires U.S. Commercial Rights to Four Branded Eye Drops
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic‑focused healthcare company, today announced its acquisition of the exclusive U.S. commercialization rights ...
Harrow Health Added to the Nasdaq Biotechnology Index
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow Health, Inc. (Nasdaq: HROW), an ophthalmic-focused healthcare company, today announced that it has been added to the Nasdaq Biotechnology Index (Nasda...
Harrow (HROW) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Harrow (HROW) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend ...
Earnings Estimates Moving Higher for Harrow (HROW): Time to Buy?
Harrow (HROW) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Harrow Health (HROW) Beats Q3 Earnings and Revenue Estimates
Harrow (HROW) delivered earnings and revenue surprises of 66.67% and 8.34%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Harrow Health Announces Third Quarter 2021 Financial Results
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced results for the third quarter and nine months ended September 3...
Harrow Health to Announce Third Quarter 2021 Financial Results on November 9, 2021
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic‑focused healthcare company, today announced that it will release its financial results for the third quarte...
Harrow Health Provides $13.5 Million Senior Secured Loan to Melt Pharmaceuticals
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow Health, Inc. (Nasdaq: HROW), an ophthalmic-focused healthcare company, and Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company develop...
Harrow Health Acquires Japan-Approved Ophthalmic Injection For Undisclosed Sum
For an undisclosed amount, Harrow Health Inc (NASDAQ: HROW) has agreed to acquire MAQ-100 U.S. and Canadian commercial rights from Wakamoto Pharmaceutical Co Ltd. MAQ-100 is a preservative-free triamcin...